Last reviewed · How we verify

Lidocaine + Esmolol (Combo)

Cedars-Sinai Medical Center · FDA-approved active Small molecule

Lidocaine blocks sodium channels to provide local anesthesia, while esmolol is a beta-1 selective adrenergic antagonist that reduces heart rate and blood pressure.

Lidocaine blocks sodium channels to provide local anesthesia, while esmolol is a beta-1 selective adrenergic antagonist that reduces heart rate and blood pressure. Used for Perioperative hemodynamic management and local anesthesia during surgical procedures.

At a glance

Generic nameLidocaine + Esmolol (Combo)
SponsorCedars-Sinai Medical Center
Drug classLocal anesthetic + Beta-1 selective adrenergic antagonist
TargetVoltage-gated sodium channels (lidocaine); Beta-1 adrenergic receptor (esmolol)
ModalitySmall molecule
Therapeutic areaAnesthesia / Perioperative Care
PhaseFDA-approved

Mechanism of action

This combination uses lidocaine's local anesthetic properties to numb tissue by inhibiting sodium influx in nerve cells, preventing pain signal transmission. Esmolol acts as a short-acting beta-blocker that selectively antagonizes beta-1 adrenergic receptors on cardiac tissue, reducing heart rate, contractility, and blood pressure. Together, they provide anesthesia with hemodynamic control, commonly used during anesthesia induction and intubation procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: